Although the prognosis of HER2-enriched breast cancer has been greatly improved through the application of anti-HER2 targeted therapy, it is still the subtype of ER-positive breast cancer with the worst prognosis18,19. This evidence concerns the gene ERBB2 and breast carcinoma.